Login to Your Account



Cyclacel Postpones Dual Listing; Evolutec Gets Less Than Sought

By Nuala Moran


Wednesday, July 28, 2004
LONDON - Cyclacel plc postponed its proposed dual listing on Nasdaq and the London Stock Exchange, citing market conditions, as Evolutec Group plc succeeded in getting its modest initial public offering away on London's Alternative Investment Market, raising £5.1 million (US$9.4 million) net of the £7.5 million net it had hoped for. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription